Partnering for Progress: A Case Study in Patient-Centered Hyperkalemia Management

ReachMD CME

Player FM - Internet Radio Done Right

191 subscribers

اضافه شده در three سال پیش

محتوای ارائه شده توسط ReachMD. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط ReachMD یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal

This Is Woman's Work with Nicole Kalil

1
The Icelandic Art of Intuition with Hrund Gunnsteinsdóttir | 307 40:34

25 روز پیش40:34

پخش در آینده

لیست ها

پسندیدن

دوست داشته شد

40:34

We’ve turned intuition into a buzzword—flattened it into a slogan, a gut feeling, or a vague whisper we don’t always know how to hear. But what if intuition is so much more? What if it's one of the most powerful tools we have—and we’ve just forgotten how to use it? In this episode, I’m joined by Hrund Gunnsteinsdóttir , Icelandic thought leader, filmmaker, and author of InnSæi: Icelandic Wisdom for Turbulent Times . Hrund has spent over 20 years studying and teaching the science and art of intuition through her TED Talk, Netflix documentary (InnSæi: The Power of Intuition), and global work on leadership, innovation, and inner knowing. Together, we explore what intuition really is (hint: not woo-woo), how to cultivate it in a culture obsessed with logic and overthinking, and why your ability to listen to yourself might be the most essential skill you can develop. In This Episode, We Cover: ✅ Why we’ve misunderstood intuition—and how to reclaim it ✅ Practical ways to strengthen your intuitive muscle ✅ What Icelandic wisdom teaches us about inner knowing ✅ How to use intuition during uncertainty and decision-making ✅ Why trusting yourself is an act of rebellion (and power) Intuition isn’t magic—it’s a deep, internal guidance system that already exists inside you. The question is: are you listening? Connect with Hrund: Website: www.hrundgunnsteinsdottir.com TedTalk: https://www.ted.com/talks/hrund_gunnsteinsdottir_listen_to_your_intuition_it_can_help_you_navigate_the_future?utm_campaign=tedspread&utm_medium=referral&utm_source=tedcomshare Newsletter: https://hrundgunnsteinsdottir.com/blog/ LI: www.linkedin.com/in/hrundgunnsteinsdottir IG: https://www.instagram.com/hrundgunnsteinsdottir/ Book: InnSæi: Icelandic Wisdom for Turbulent Times Related Podcast Episodes: How To Breathe: Breathwork, Intuition and Flow State with Francesca Sipma | 267 VI4P - Know Who You Are (Chapter 4) Gentleness: Cultivating Compassion for Yourself and Others with Courtney Carver | 282 Share the Love: If you found this episode insightful, please share it with a friend, tag us on social media, and leave a review on your favorite podcast platform! 🔗 Subscribe & Review: Apple Podcasts | Spotify | Amazon Music Learn more about your ad choices. Visit megaphone.fm/adchoices…

MP3•خانه قسمت

CME credits: 0.25
Valid until: 17-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/partnering-for-progress-a-case-study-in-patient-centered-hyperkalemia-management/26749/
Hyperkalemia is a common complication in patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. Join Dr. David Wheeler as he explores strategies for managing hyperkalemia while optimizing treatment benefits. Learn about patient-centered communication techniques, risk factors, and treatment options. Discover the importance of ongoing monitoring and follow-up to ensure optimal management. You don’t want to miss this opportunity to improve your clinical practice and enhance patient outcomes.

424 قسمت

#Science #Health and Well-Being #Medicine #ReachMD

ReachMD CME

Partnering for Progress: A Case Study in Patient-Centered Hyperkalemia Management

ReachMD CME

191 subscribers

published حدود یک سال پیش

اشتراک گذاری

MP3•خانه قسمت

424 قسمت

#Science #Health and Well-Being #Medicine #ReachMD

Alle afleveringen

ReachMD CME

1
Practical Tips for GLP-1 RA Therapy Success

۲ روز پیش

—

CME credits: 0.50 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/practical-tips-for-glp-1-ra-therapy-success/35830/ This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.…

ReachMD CME

1
Beyond the Scale: How to Tackle Obesity’s Comorbidities

۲ روز پیش

—

CME credits: 0.50 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/beyond-the-scale-how-to-tackle-obesitys-comorbidities/35829/ This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.…

ReachMD CME

1
Treating Obesity: Lifelong Strategies from Lifestyle to Pharmacotherapy and Surgery Treating Obesity: Lifelong Strategies fFrom Lifestyle to Pharmacotherapy and Surgery

۲ روز پیش

—

CME credits: 0.50 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/treating-obesity-lifelong-strategies-from-lifestyle-to-pharmacotherapy-and-surgery-treating-obesity-lifelong-strategies-ffrom-lifestyle-to-pharmacotherapy-and-surgery/35828/ This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.…

ReachMD CME

1
Obesity and Comorbidities: Strategies for Effective Patient Management

۲ روز پیش

—

CME credits: 0.50 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/obesity-and-comorbidities-strategies-for-effective-patient-management/35827/ This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.…

ReachMD CME

1
Obesity: Unmasking the Chronic Disease Beneath the Weight

۲ روز پیش

—

CME credits: 0.50 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/obesity-unmasking-the-chronic-disease-beneath-the-weight/35826/ This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.…

ReachMD CME

1
Second-line Chemotherapy Options in Metastatic PDAC

۷ weeks پیش

—

CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/second-line-chemotherapy-options-in-metastatic-pdac/33136/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This two-part programme provides an overview of the different first- and second-line chemotherapy options. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma…

ReachMD CME

1
First-line Chemotherapy Options in Metastatic PDAC

۷ weeks پیش

—

CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/first-line-chemotherapy-options-in-metastatic-pdac/33135/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This two-part programme provides an overview of the different first- and second-line chemotherapy options. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma…

ReachMD CME

1
Revolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression

۸ weeks پیش

—

CME credits: 0.50 Valid until: 04-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/revolutionizing-diagnostic-precision-ai-driven-approaches-in-digital-pathology-and-her2-expression/29878/ With the availability of HER2-directed therapies, it’s important to accurately identify patients who would benefit from these therapies, particularly in breast cancer, where we now have a spectrum of HER2 positivity. Advances in technology have augmented the role of digital pathology (DP) and artificial intelligence (AI) in oncologic pathology. This activity demonstrates how DP/AI can be used for more accurate biomarker assessment and explores the impact this may have on patient outcomes.…

ReachMD CME

1
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers

۸ weeks پیش

—

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/establishing-best-practices-for-collaborative-care-for-patients-with-ascvd-between-academic-and-rural-providers/29824/ This on-demand knowledge primer explores key challenges and evidence-based strategies for improving atherosclerotic cardiovascular disease (ASCVD) management in rural populations. Led by two expert faculty members, the program provides a comprehensive overview of disparities in ASCVD care, guideline-directed therapies, and practical approaches to overcoming barriers in rural settings. Participants will gain essential knowledge to enhance patient outcomes and optimize cardiovascular care in underserved communities.…

ReachMD CME

1
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection

۹ weeks پیش

—

CME credits: 0.75 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-clinical-and-laboratory-criteria-for-diagnosis-and-optimal-treatment-selection/29533/ The adult and pediatric diagnostic and treatment landscapes of generalized myasthenia gravis (gMG) are both similar and different. While current traditional therapies are often effective in the short term, selecting the most appropriate short- and longer-term treatment for each patient, whether adult or pediatric, brings with it unique individual challenges. These challenges include how best to utilize newer targeted agents in the treatment of gMG, such as the neonatal Fc receptor (FcRn) inhibitors. Join Drs. Vera Bril and Jonathan Strober as they tackle these issues from both the adult and pediatric perspective.…

ReachMD CME

1
Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles

۹ weeks پیش

—

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-for-gmg-tailoring-treatments-based-on-patient-profiles/32735/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.…

ReachMD CME

1
Preventing Myasthenic Crisis: Early Signs and Critical Interventions

۹ weeks پیش

—

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/preventing-myasthenic-crisis-early-signs-and-critical-interventions/32734/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.…

ReachMD CME

1
Ocular to Generalized MG: How and Why the Disease Evolves

۹ weeks پیش

—

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/ocular-to-generalized-mg-how-and-why-the-disease-evolves/32733/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.…

ReachMD CME

1
Managing Side Effects in FcRn Therapy: Best Practices for gMG

۹ weeks پیش

—

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-side-effects-in-fcrn-therapy-best-practices-for-gmg/32732/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.…

ReachMD CME

1
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy

۹ weeks پیش

—

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/new-frontiers-in-mg-how-fcrn-antagonists-are-changing-mg-therapy/32731/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.…

به Player FM خوش آمدید!

Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.

به بیش از 500 موضوع گوش کنید

191 subscribers

مشابه ReachMD CME

$25 PlayStation Store Gift Card [Digital Code]

reputation [2 LP][Picture Disc]

Bounty Quick Size Paper Towels, White, 8 Family Rolls = 20 Regular Rolls (Packaging May Vary)

پادکست هایی که ارزش شنیدن دارند

ReachMD CME « » Partnering for Progress: A Case Study in Patient-Centered Hyperkalemia Management

Partnering for Progress: A Case Study in Patient-Centered Hyperkalemia Management

پادکست هایی که ارزش شنیدن دارند

به Player FM خوش آمدید!

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

Bounty Paper Towels Quick Size, White, 16 Family Rolls = 40 Regular Rolls (Packaging May Vary)

2025 Topps Series 1 Baseball - Factory Sealed - Value Box

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

مشابه ReachMD CME

راهنمای مرجع سریع

ReachMD CME « »
Partnering for Progress: A Case Study in Patient-Centered Hyperkalemia Management